3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
4
Cetuximab
4
Pemetrexed
3
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
2
Gemcitabine
2
pembrolizumab
1
monalizumab
1
durvalumab
1
X-Rays
1
Vitamin B 12
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiation
1
Proflavine
1
Paclitaxel
1
Modafinil
1
Minocycline
1
Metformin
1
Gefitinib
1
Gabapentin
1
Folic Acid
1
Fibroblast Growth Factor 7
1
Drug Therapy
1
Docetaxel
1
Chemical Fractionation
1
Carboplatin
1
Bupropion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Laryngeal Diseases
×
monalizumab
×
Clear all
NCT04590963
2026-06-01
INTERLINK-1
AstraZeneca
Phase 3
Active not recruiting
370 enrolled
21 charts